L3VLUP
ProSign in

DNA · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DNAARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DNA
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterDNAARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 2020none listed holders, n.a.7 holders, $4.1bn
Q1 2021none listed holders, n.a.8 holders, $4.1bn
Q2 2021none listed holders, n.a.9 holders, $4.6bn
Q3 2021none listed holders, n.a.8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 2022none listed holders, n.a.8 holders, $5.3bn
Q2 2022none listed holders, n.a.13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 2022none listed holders, n.a.13 holders, $5.5bn
Q1 2023none listed holders, n.a.13 holders, $5.9bn
Q2 2023none listed holders, n.a.18 holders, $6.6bn
Q3 2023none listed holders, n.a.21 holders, $8.7bn
Q4 2023none listed holders, n.a.17 holders, $6.3bn
Q1 2024none listed holders, n.a.13 holders, $6.8bn
Q2 2024none listed holders, n.a.14 holders, $7.9bn
Q3 20245 holders, $62m13 holders, $10.7bn
Q4 20244 holders, $72m14 holders, $12.3bn
Q1 20254 holders, $43m17 holders, $11.8bn
Q2 20254 holders, $80m18 holders, $10.8bn
Q3 20255 holders, $104m16 holders, $13.8bn
Q4 20254 holders, $52m16 holders, $14.8bn
Q1 20262 holders, $37m11 holders, $12.3bn
Q2 20263 holders, $61m14 holders, $15.0bn
DNA

Ginkgo Bioworks Holdings Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$7.9bn
Buyers
9
Sellers
7

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2024

Among the 14 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only DNA (0)

None.

Only ARGX (14)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →